Single agent anti-PD-1 versus combined BRAF and MEK inhibitors upfront in metastatic or unresectable BRAF V600 mutated melanoma - A EUMelaReg real world evidence study
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Treatment of BRAFV600 mutated metastatic melanoma patients with either BRAF and MEK inhibitors (BRAF/MEKi) or immune-checkpoint inhibitors (ICI) with anti-PD-1 antibodies or anti-PD-1/CTLA-4 combinations, has improved the outcome of patients significantly compared to former treatment standards. While some evidence is available for advantage of combined anti-PD-1/CTLA-4 antibody treatment compared to BRAF/MEKi, the role of single agent anti-PD-1 antibody treatment is less clear.
Source: EJC Skin Cancer
Institutions: University Hospital Schleswig-Holstein, Military Medical Academy, Rabin Medical Center, The Netherlands Cancer Institute, University Hospital Zurich, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", National and Kapodistrian University of Athens, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Universitario La Paz, Centro de Investigación Biomédica en Red de Cáncer, Essen University Hospital, Stiftung Universitätsmedizin Essen, Odense University Hospital
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409145113